ReviewBiologics : targets & therapy2021
Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician.
Review in Biologics : targets & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of non-conventional synthetic disease-modifying antirheumatic drugs in early active rheumatoid arthritis: a network meta-analysis.BMC rheumatology · 2025Pooled it
- Modulating inflammation and oxidative stress in rheumatoid arthritis: a systematic review of nutraceutical interventions.Inflammopharmacology · 2025Pooled it
- Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal Analysis.Drug safety · 2026Article
- Fibroblast-like Synoviocytes as Therapeutic Targets in Rheumatoid Arthritis: Current Evidence on DMARD-Mediated Modulation.Biomedicines · 2026Review
- [Consequences of late access to specialist care-effect on medication costs in rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2026Article
- IL-6 Receptor Antagonists and Severe Post-COVID-19 Outcomes: An Emulated Target Trial.medRxiv : the preprint server for health sciences · 2026Article
- Rituximab as monotherapy and in combination with methotrexate or leflunomide in rheumatoid arthritis: a prospective cohort study in a Peruvian hospital.Reumatologia · 2026Article
- Platelet-rich Plasma: ACurrent drug research reviews · 2026Review
- Looking to the new horizon in rheumatology research.Nature reviews. Rheumatology · 2025Article
- Nurses' Role in Patient Education for Managing Inflammatory Joint Diseases: Insights from a Cross-Sectional Survey in Bulgarian Rheumatology Clinics.Healthcare (Basel, Switzerland) · 2025Article
- Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study.EULAR rheumatology open · 2025Article
- The Dental Status of Patients Taking Common Biologic Agents: A Single-Center Cross-Sectional Study.Oral diseases · 2025Article
- Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Comprehensive lipoprotein and glycoprotein characterization in rheumatoid arthritis plasma and association with clinical markers.Frontiers in molecular biosciences · 2025Article
- Transcriptomic Analysis of Blood Collagen-Induced Arthritis Mice Exposed to 0.1 THz Reveals Inhibition of Genes and Pathways Involved in Rheumatoid Arthritis.International journal of molecular sciences · 2024Article
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Article
- Advancements in Immunology and Microbiology Research: A Comprehensive Exploration of Key Areas.Microorganisms · 2024Review
- Digital Therapeutics for Improving Effectiveness of Pharmaceutical Drugs and Biological Products: Preclinical and Clinical Studies Supporting Development of Drug + Digital Combination Therapies for Chronic Diseases.Journal of clinical medicine · 2024Review
- Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the "real-world" use of bDMARDs and how they fit into the overall RA treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.